Search Results

Your search for Syed A. Abutalib, MD, and Katharina Fleischhauer, MD,Syed A. Abutalib, MD, and Katharina Fleischhauer, MD matches 2 pages

Showing 1 - 2

By Syed A. Abutalib, MD, and Katharina Fleischhauer, MD / October 25, 2016

Donor Selection for HLA-Matched Hematopoietic Cell Transplantation

Question 1: Which statement about donor selection for allogeneic hematopoietic cell transplant is correct? Correct Answer: C. If a donor is available, the genotypic identity between the patient and his brother should be established by typing the patient’s parents; if this is not possible, the...

leukemia

By Syed A. Abutalib, MD, and Katharina Fleischhauer, MD / October 25, 2016

Donor Selection for HLA-Matched Hematopoietic Cell Transplantation

Case Study A 33-year-old white male is diagnosed with acute myeloid leukemia (AML) with complex cytogenetics. A decision is made in favor of performing allogeneic hematopoietic cell transplantation in first complete remission. The patient has a 35-year-old brother who is healthy and motivated to...

Oct

Today In Oncology

Search Results

Your search for Syed A. Abutalib, MD, and Katharina Fleischhauer, MD,Syed A. Abutalib, MD, and Katharina Fleischhauer, MD matches 2 pages

Donor Selection for HLA-Matched Hematopoietic Cell Transplantation

Donor Selection for HLA-Matched Hematopoietic Cell Transplantation

Second-Line Sotorasib Plus Afatinib for KRAS-Mutant NSCLC

Poziotinib a Tyrosine Kinase Inhibitor for HER2 Exon 20–Mutant NSCLC

Adjuvant Atezolizumab Following Adjuvant Chemotherapy for Resected Stage IB to IIIA NSCLC

FDA Approves Atezolizumab as Adjuvant Treatment for NSCLC

Mobocertinib for Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic NSCLC